A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
Maria Concetta Fargnoli, Maria Esposito, Silvia Mariel Ferrucci, Giampiero Girolomoni, Anna Maria Offidani, Annalisa Patrizi, Ketty Peris, Antonio Costanzo, Giovanna Malara, Giovanni Pellacani, Marco Romanelli, Paolo Amerio, Antonio Cristaudo, Maria Laura Flori, Alberico Motolese, P. Betto, Cataldo Patruno, Paolo D. Pigatto, Camilla Peccianti, Giuseppe Stinco, Iris Zalaudek, Luca Bianchi, Valeria Boccaletti, Serafinella Patrizia Cannavò, Francesco Cusano, Serena Lembo, R. Mozzillo, Rosella Gallo, Concetta Potenza, Franco Rongioletti, R. Tiberio, Teresa Grieco, Giuseppe Micali, Severino Persechino, M. Pettinato, Sabina Pucci, Luca Stingeni, Cristiano Caruso, Giuseppe Argenziano
Abstract
The long-term efficacy and safety of dupilumab has been demonstrated in clinical trials and only in few real-world studies. We conducted an extension analysis from a previous 16-week study on 109 adult patients affected by moderate-to-severe atopic dermatitis treated with dupilumab. Eczema-Area-and-Severity-Index (EASI), itch numerical-rating-score (itch-NRS), Dermatology-Life-Quality-Index (DLQI) scores, drug survival rate and occurrence of adverse events after 24 and 48 weeks of dupilumab treatment were retrospectively collected. Dupilumab demonstrated sustained improvement of disease severity, pruritus, and quality of life in our series with an increasing percentage of patients gaining EASI75 and EASI90 response during the study period. Few patients interrupted treatment resulting in a very high drug survival rate. We also confirmed the favorable safety profile of the drug with absence of serious adverse events and serious infections throughout the 48-week period. The prevalence of conjunctivitis was low and mainly occurred in the mid-term with resolution of the majority of cases at 48 weeks.